Insulin inhalation - Abbott Laboratories
Alternative Names: KI 02 212Latest Information Update: 21 Jan 2022
Price :
$50 *
At a glance
- Originator Kos Pharmaceuticals
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
- 31 Mar 2005 Kos Pharmaceuticals has filed an IND with the US FDA for diabetes mellitus
- 02 Sep 2004 Phase-II clinical trials in Diabetes mellitus in USA (Inhalation)